FDA Category 2 Peptide Ban: The Complete Guide

The FDA maintains a system for classifying substances that compounding pharmacies can use to prepare medications. This system is part of the regulatory framework under Section 503A of the Federal Food, Drug, and Cosmetic Act, which governs pharmacy compounding.

Category 1 substances are bulk drug substances that compounding pharmacies can use to prepare patient-specific medications with valid prescriptions. Most traditional compounding ingredients fall into this category. Being in Category 1 does not mean the substance is FDA-approved for any indication — it simply means compounding pharmacies can legally use it.

Category 2 substances are those the FDA has flagged as presenting "potential significant safety risks" or having "insufficient data to support safe compounding." When a substance is placed on Category 2, compounding pharmacies are effectively prohibited from using it to prepare medications.

Category 3 substances are under active evaluation — the FDA is still reviewing data and has not made a final determination.

The distinction matters enormously for patient access. For substances like BPC-157 or CJC-1295 that were never FDA-approved as drugs but were widely used through compounding pharmacies, being moved to Category 2 eliminated the only legal pathway for patients to obtain them.

Between late 2023 and December 2024, the FDA moved 19 popular peptides from Category 1 to Category 2 on the 503A Bulk Drug Substances list. This was the largest single restriction of compounding substances in recent history and had immediate, widespread effects on patient access.

The FDA's stated rationale included several concerns: insufficient published safety data for most of these peptides in human clinical use, potential for immune reactions (particularly with thymosin-family peptides like thymosin alpha-1 and thymosin beta-4), manufacturing and impurity concerns specific to peptide compounding (peptides are more complex to synthesize and more prone to degradation than small-molecule drugs), and the argument that for some indications, FDA-approved alternatives existed.

The timing and process. The FDA did not announce all 19 restrictions at once. The list expanded over a period of months, with peptides added in batches. This rolling approach created confusion among providers and patients, as the legal status of specific compounds changed without broad public communication. Many patients learned their prescriptions could no longer be filled only when they attempted to obtain refills.

Industry response. The compounding pharmacy industry, represented by organizations like the Alliance for Pharmacy Compounding, pushed back aggressively. They argued that the FDA was overreaching its authority, that the safety concerns were not substantiated by adverse event data proportional to use volume, and that removing access would harm patients who depended on these compounds. Legal challenges were filed but moved slowly through the courts.

Patient impact. For patients who had been using compounded peptides under physician supervision — sometimes for years — the restrictions were abrupt and disruptive. Patients using BPC-157 for inflammatory gut conditions, CJC-1295/ipamorelin for growth hormone optimization, or thymosin alpha-1 for immune support suddenly lost access. Some turned to gray-market sources, which raised new safety concerns.

The following peptides were placed on Category 2 between late 2023 and December 2024. We have organized them by primary use category for clarity.

Tissue repair and healing: BPC-157 (the most widely used compounding peptide, used for gut healing, tendon/ligament repair, and musculoskeletal recovery) and Thymosin Beta-4/TB-500 (used for tissue repair, cardiac protection, and wound healing).

Growth hormone secretagogues: CJC-1295 (with and without DAC, used to stimulate growth hormone release), Ipamorelin (selective GH secretagogue, often combined with CJC-1295), AOD-9604 (GH fragment, used for fat loss), and Sermorelin (later returned to Category 1 before the broader reclassification).

Immune modulation: Thymosin Alpha-1 (used for immune enhancement in immunocompromised patients, had significant clinical use history), KPV (anti-inflammatory tripeptide derived from alpha-MSH), and MOTS-c (mitochondrial-derived peptide with metabolic and immune effects).

Cognitive and neurological: Selank (anxiolytic peptide developed in Russia with extensive foreign clinical data), Semax (nootropic peptide, also with Russian clinical use history), Dihexa (potent nootropic peptide), and PE-22-28 (neuroprotective peptide).

Skin, anti-aging, and other: GHK-Cu (copper peptide — notably already available in OTC cosmetics, making the compounding restriction somewhat unusual), Epithalon (telomerase-activating tetrapeptide), and 5-Amino-1MQ (NNMT inhibitor used for metabolic enhancement).

Notable exception: Sermorelin was initially placed on Category 2 but was subsequently reviewed and returned to Category 1 before the February 2026 announcement, based on its more extensive clinical use history and existing FDA NDA records. This set a precedent that suggested the FDA was open to case-by-case reconsideration.

The debate over whether the Category 2 restrictions were appropriate hinges on a fundamental question: how much evidence should be required before the government restricts access to compounds that physicians and patients have been using?

The FDA's position was that most of these peptides lacked adequate published human safety data for the routes of administration, doses, and durations commonly used in compounding. While many had extensive animal data and foreign clinical use, the FDA argued this was insufficient under US regulatory standards. The FDA also cited specific safety signals: potential immunogenicity of thymosin peptides, contamination risks in peptide compounding, and theoretical concerns about long-term effects.

The opposing position argued that adverse event reports for compounded peptides were extremely low relative to their use volume, that the FDA was applying an inappropriately high evidence bar to compounding (which has historically operated under a different standard than new drug approval), and that removing access caused concrete harm to patients who were benefiting from these treatments under physician supervision.

The nuanced reality is somewhere between these positions. The FDA was correct that the human evidence base for most of these peptides is thin — BPC-157, for example, has over 100 animal studies but virtually no controlled human trials. At the same time, the adverse event signal was genuinely low given the estimated use volume. The question is whether the precautionary principle justified restricting access in the absence of a clear safety signal, or whether the restriction was disproportionate to the demonstrated risk.

On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 peptides on the Category 2 list would return to Category 1, restoring compounding access. This represented the most significant rollback of FDA compounding restrictions in recent history.

What has changed: The policy direction is clear — the current administration intends to restore compounding access for the majority of restricted peptides. This reflects both the political environment (Kennedy's stated emphasis on patient choice and skepticism of regulatory overreach) and the practical reality that the restrictions had not measurably improved patient safety while causing documented harm through loss of access.

What has NOT changed yet: As of this writing (March 2026), the formal FDA list update has not been published. Until official publication in the Federal Register, the legal status technically remains unchanged. Compounding pharmacies that resume production before formal publication take some regulatory risk, though enforcement in the current political environment appears unlikely.

Peptides remaining restricted: TB-500 (thymosin beta-4) is expected to remain on Category 2, along with potentially 4-5 other compounds. The specific rationale for each retention has not been publicly detailed, but TB-500's theoretical concerns about cancer cell proliferation appear to have weighed against it.

Timeline. The formal reclassification is expected within weeks to months. We maintain current regulatory status on every compound page in our database and will update immediately when formal changes are published. Patients and providers should verify status before resuming compounding relationships.

For patients and providers navigating the evolving regulatory landscape, here is a practical framework.

If you were previously using compounded peptides: Contact your prescribing physician and compounding pharmacy to discuss the timeline for resuming access. Verify that your pharmacy will wait for formal FDA publication before resuming production. Consider whether the compound you used is among the 14 expected to return (or the ~5 expected to remain restricted). Do not obtain peptides from unregulated sources while waiting for formal reclassification.

If you are new to peptides: The reclassification changes the legal access picture but not the evidence picture. Before starting any peptide therapy, research the evidence for your specific condition using resources that present the data accurately (including limitations). Work with a physician who is knowledgeable about peptide therapy and transparent about evidence gaps. Choose a compounding pharmacy with strong quality credentials (PCAB accreditation, third-party testing, COAs). Start with established protocols and monitor with appropriate lab work.

If you are a provider: Stay current with the formal FDA list updates through the FDA's 503A Bulk Drug Substances page. Ensure your compounding pharmacy partners meet quality standards. Document informed consent thoroughly, including the distinction between compounding access and FDA approval. Monitor patients with appropriate baseline and follow-up testing.

Red flags to avoid: Online sellers offering peptides without prescriptions (illegal regardless of Category status). Claims that reclassification means "FDA approved" (it does not). Providers who guarantee results or minimize evidence gaps. Unusually low prices that suggest compromised quality.